Diffusion Pharmaceuticals (NASDAQ:DFFN) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) in a report published on Saturday morning. The firm issued a hold rating on the stock.

Diffusion Pharmaceuticals Stock Up 2.5 %

NASDAQ DFFN traded up $0.15 on Friday, reaching $6.06. 854 shares of the company’s stock traded hands, compared to its average volume of 5,842. Diffusion Pharmaceuticals has a 12 month low of $4.64 and a 12 month high of $19.80. The stock has a 50-day simple moving average of $6.09 and a 200 day simple moving average of $5.81.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. purchased a new stake in Diffusion Pharmaceuticals in the first quarter worth $106,000. Renaissance Technologies LLC lifted its stake in Diffusion Pharmaceuticals by 8.3% in the first quarter. Renaissance Technologies LLC now owns 1,324,202 shares of the company’s stock worth $331,000 after acquiring an additional 101,100 shares during the period. Finally, Trexquant Investment LP purchased a new stake in Diffusion Pharmaceuticals in the second quarter worth $71,000. Institutional investors own 9.24% of the company’s stock.

Diffusion Pharmaceuticals Company Profile

(Get Rating)

Diffusion Pharmaceuticals, Inc is a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen. The firm’s product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia.